Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426286 | 0.86 | TLR8 (0.55) | TLR8TLR7JAK2JAK1TYK2 | |
| SCHEMBL25089560 | 0.85 | CNR2 (0.49) | MAPTTLR7ACSS2KDM4EALOX15 | |
| SCHEMBL1637181 | 0.83 | KDM4E (0.42) | TLR8TLR7ACSS2KDM4E | |
| SCHEMBL30676114 | 0.81 | ACSS2 (0.46) | MAPTACSS2KDM4EALOX15HTT | |
| SCHEMBL20266433 | 0.81 | ACSS2 (0.46) | MAPTACSS2KDM4EALOX15HTT | |
| SCHEMBL23901856 | 0.76 | KLK1 (0.50) | MAPTJAK2JAK1TYK2JAK3 | |
| SCHEMBL31721245 | 0.75 | HTT (0.49) | MAPTACSS2KDM4EALOX15HTT | |
| SCHEMBL3596405 | 0.75 | NPC1 (0.61) | MAPTACSS2KDM4EALOX15HTT | |
| SCHEMBL9570434 | 0.75 | KDM4E (0.54) | MAPTKDM4E | |
| SCHEMBL9597830 | 0.75 | KDM4E (0.54) | MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | MAPT 3333/4885TLR8 1484/4885TLR7 761/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | MAPT 3184/4885TLR8 1783/4885TLR7 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.